WO2006125181A3 - Piperidine derivatives and their use as stearoyl-coa desaturase modulators - Google Patents

Piperidine derivatives and their use as stearoyl-coa desaturase modulators Download PDF

Info

Publication number
WO2006125181A3
WO2006125181A3 PCT/US2006/019566 US2006019566W WO2006125181A3 WO 2006125181 A3 WO2006125181 A3 WO 2006125181A3 US 2006019566 W US2006019566 W US 2006019566W WO 2006125181 A3 WO2006125181 A3 WO 2006125181A3
Authority
WO
WIPO (PCT)
Prior art keywords
stearoyl
piperidine derivatives
coa desaturase
desaturase modulators
modulators
Prior art date
Application number
PCT/US2006/019566
Other languages
French (fr)
Other versions
WO2006125181A2 (en
Inventor
Jianmin Fu
Vishnumurthy Kodumuru
Shifeng Liu
Original Assignee
Xenon Pharmaceuticals Inc
Jianmin Fu
Vishnumurthy Kodumuru
Shifeng Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Jianmin Fu, Vishnumurthy Kodumuru, Shifeng Liu filed Critical Xenon Pharmaceuticals Inc
Publication of WO2006125181A2 publication Critical patent/WO2006125181A2/en
Publication of WO2006125181A3 publication Critical patent/WO2006125181A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where p, G, J, L, M, W, R2, R3, R4 and R5 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
PCT/US2006/019566 2005-05-19 2006-05-19 Piperidine derivatives and their use as stearoyl-coa desaturase modulators WO2006125181A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68246505P 2005-05-19 2005-05-19
US60/682,465 2005-05-19

Publications (2)

Publication Number Publication Date
WO2006125181A2 WO2006125181A2 (en) 2006-11-23
WO2006125181A3 true WO2006125181A3 (en) 2007-03-29

Family

ID=37432189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019566 WO2006125181A2 (en) 2005-05-19 2006-05-19 Piperidine derivatives and their use as stearoyl-coa desaturase modulators

Country Status (1)

Country Link
WO (1) WO2006125181A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050124A1 (en) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
EP2086970B1 (en) 2006-08-24 2014-02-26 Novartis AG 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (en) 2007-01-26 2009-05-06 Merck Frosst Canada Inc DERIVATIVES OF AZACICLOALCANS AS INHIBITORS OF ESTEAROIL - COENZIMA A DELTA -9 DESATURASA
WO2008096746A1 (en) 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited Spiro compound and use thereof
JP5597210B2 (en) 2009-02-17 2014-10-01 メルク カナダ インコーポレイテッド Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2850836A1 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
KR20150013777A (en) 2012-05-22 2015-02-05 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. Selective inhibitors of undifferentiated cells
MA46589A (en) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc COMPOUNDS AND USES OF THE LATEST
JP2020514293A (en) 2017-01-06 2020-05-21 ユマニティ セラピューティクス，インコーポレーテッド How to treat neuropathy
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011657A2 (en) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
WO2005042542A1 (en) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011657A2 (en) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
WO2005042542A1 (en) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRAHN, M.S. ET AL.: "Radiation-induced polymerization monitored in situ by time-resolved fluorescence of probe molecules in methyl methacrylate", NUCLEAR INSTRUMENTS AND METHODS IN PHYSICS RESEARCH B, vol. 208, 2003, pages 405 - 410, XP002411451 *
HUANG T L ET AL: "Synthesis and anti-Pneumocystis carinii activity of piperidine-linked aromatic diimidazolines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 17, 1996, pages 2087 - 2090, XP002227683, ISSN: 0960-894X *
LAUTESLAGER, X.Y. ET AL.: "Conformational dynamics of charge-transfer states in donor-bridge-acceptor systems", EUR. J. ORG. CHEM., vol. 16, 2001, pages 3105, XP002411450 *
SCHERER T ET AL: "Synthesis and exploratory photophysical investigation of donor-bridge-acceptor systems derived from N-substituted 4-piperidones", RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS, ELSEVIER SCIENCE PUBLISHERS. AMSTERDAM, NL, vol. 112, no. 10, October 1993 (1993-10-01), pages 535 - 548, XP002087998, ISSN: 0165-0513 *

Also Published As

Publication number Publication date
WO2006125181A2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2006125181A3 (en) Piperidine derivatives and their use as stearoyl-coa desaturase modulators
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
WO2007136746A3 (en) Macrocyclic compounds and their uses as stearoyl-coa desaturase
EP2266569A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2269610A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006086447A3 (en) Pyridazine derivatives and their use as therapeutic agents
MX2007000028A (en) Nicotinamide derivatives and their use as therapeutic agents.
MX2007003327A (en) Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase.
WO2006034315A3 (en) Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
WO2007138472A3 (en) Triazolopyridazine derivatives
TW200626153A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2005011657A3 (en) Piperazine derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2006125178A3 (en) Tricyclic pyridazine compounds and their uses as therapeutic agents
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006100081A3 (en) Substituted oxindole derivatives, medicaments containing the latter and use thereof
WO2006072458A3 (en) Substituted oxindole derivatives, medicaments containing said derivatives and use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06770730

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06770730

Country of ref document: EP

Kind code of ref document: A2